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Despite advances in diagnosis, surgery, and antimicrobial therapy, mortality rates associated with complicated
intra-abdominal infections remain exceedingly high.
The 2013 update of the World Society of Emergency Surgery (WSES) guidelines for the management of
intra-abdominal infections contains evidence-based recommendations for management of patients with
intra-abdominal infections.Introduction
The clinical recommendations discussed in these guide-
lines are based on research conducted by members of
the WSES Expert Panel. These updated guidelines re-
place those previously published in 2010 [1]. The guide-
lines outline clinical recommendations based on the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) hierarchy criteria summarized
in Table 1 [2,3].Principles of surgical management
Intra-abdominal infections (IAIs) encompass a variety of
pathological conditions, ranging from uncomplicated ap-
pendicitis to fecal peritonitis [4].
As a general principle, every verified source of infec-
tion should be controlled as soon as possible. The level
of urgency of treatment is determined by the affected
organ(s), the relative speed at which clinical symptoms* Correspondence: m.sartelli@virgilio.it
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reproduction in any medium, provided the orprogress and worsen, and the underlying physiological
stability of the patient.
The procedure used to treat the infection depends on
the anatomical site of infection, the degree of peritoneal
inflammation, the generalized septic response, the pa-
tient’s underlying condition, and the available resources
of the treatment center. IAIs are subcategorized in 2
groups: uncomplicated and complicated IAIs [5].
In the event of an uncomplicated case of IAI, the in-
fection involves a single organ and does not spread to
the peritoneum. Patients with such infections can be
treated with either surgical intervention or antibiotics.
When the infection is effectively resolved by means of
surgery, a 24-hour regimen of perioperative antibiotics is
typically sufficient. Patients with uncomplicated intra-
abdominal infections, such as acute diverticulitis, acute
cholecystitis, and acute appendicitis, may be treated non-
operatively by means of antimicrobial therapy.
In the event of complicated IAI, the infectious process
proceeds beyond a single organ, causing either loca-
lized or diffuse peritonitis. The treatment of patients withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Grading of recommendations from Guyatt and colleagues [1,2]
Grade of recommendation Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from observational
studies
Strong recommendation, applies to most
patients in most circumstances without
reservation
1B
Strong recommendation,
moderate-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or
imprecise) or exceptionally strong evidence
from observational studies
Strong recommendation, applies to most
patients in most circumstances without
reservation
1C
Strong recommendation,
low-quality or very low-
quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case series Strong recommendation based on limited
evidence; recommendations may change
when higher quality or more extensive
evidence becomes available
2A
Weak recommendation,
high-quality evidence
Benefits closely balanced with
risks and burdens
RCTs without important limitations or
overwhelming evidence from observational
studies
Weak recommendation, best action may
differ depending on circumstances,
expertise of clinician, the patient in
question, or other social issues
2B
Weak recommendation,
moderate-quality evidence
Benefits closely balanced with
risks and burdens
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or
imprecise) or exceptionally strong evidence
from observational studies
Weak recommendation, best action may
differ depending on circumstances,
expertise of clinician, the patient in
question, or other social issues
2C
Weak recommendation,
Low-quality or very low-
quality evidence
Uncertainty in the estimates
of benefits, risks, and burdens;
benefits, risks, and burdens
may be closely balanced
Observational studies or case series Very weak recommendation; other
alternatives may be equally reasonable
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gical and antibiotic therapy [5].
The safety and efficacy of ultrasound- and CT-guided
percutaneous drainage of abdominal abscesses has been
documented in patients with appendiceal and diverticular
abscesses. Percutaneous image-guided drainage may also
be used to address cases of advanced acute cholecystitis.
Sepsis management
Patients with severe sepsis or septic shock of abdominal
origin require early hemodynamic support, source con-
trol, and antimicrobial therapy (Recommendation 1A).
Abdominal sepsis occurs as result of intra-abdominal
or retroperitoneal infection. Early detection of the site of
infection and timely therapeutic intervention are cru-
cial steps for improving the treatment outcome of sepsis
patients.
Sepsis is a complex, multifactorial, evolutive syndrome
that can progress to conditions of varying severity. If im-
properly treated, it may cause the functional impairment
of one or more vital organs or systems, which could lead
to multiple organ failure [6]. Previous studies have de-
monstrated that there is an increased risk of death as
patients transition from sepsis to severe sepsis and septic
shock [7]. In the context of intra-abdominal infections,severe sepsis represents the diagnostic threshold separat-
ing stable and critical clinical conditions.
Thus, early detection of severe sepsis and prompt, ag-
gressive treatment of the underlying organ dysfunction
is an essential component of improving patient outcome.
If untreated, sepsis dysfunction can lead to global tissue
hypoxia, direct tissue damage, and ultimately to multiple
organ failure [8-10].
Sepsis in the surgical patient continues to be a com-
mon and potentially lethal problem. Early identification
of patients and timely implementation of evidence-based
therapies continue to represent significant clinical chal-
lenges for care providers. The implementation of a sepsis
screening program in conjunction with protocol for the
delivery of evidence-based care and rapid source control
can improve patient outcomes [11].
Early, correctly administered resuscitation can im-
prove the outcome of patients with severe sepsis and
septic shock (Recommendation 1A).
Rivers et al. demonstrated that a strategy of early goal-
directed therapy (EGDT) decreases the in-hospital mor-
tality of patients admitted to the emergency department
in septic shock [9].
In surgical patients early intervention and implemen-
tation of evidence-based guidelines for the management
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patients with sepsis [12].
Patients with severe sepsis and septic shock may pre-
sent with inadequate perfusion. Poor tissue perfusion can
lead to global tissue hypoxia and, in turn, to elevated levels
of serum lactate. Fluid resuscitation should be initiated as
early as possible in patients with severe sepsis.
The Surviving Sepsis Campaign guidelines [10] re-
commend that fluid challenge in patients with suspected
hypovolemia begin with >1000 mL of crystalloids or
300–500 mL of colloids administered over a period of
30 minutes. Quicker administration and greater volumes
of fluid may be required for patients with sepsis-induced
tissue hypoperfusion. Given that the volume of distri-
bution is smaller for colloids than it is for crystal-
loids, colloid-mediated resuscitation requires less fluid
to achieve the same results. A colloid equivalent is an
acceptable alternative to crystalloid, though it should
be noted that crystalloids are typically less expensive.
When fluid challenge fails to restore adequate arterial
pressure and organ perfusion, clinicians should resort to
vasopressor agents. Vasopressor drugs maintain adequate
blood pressure and preserve perfusion pressure, thereby
optimizing blood flow in various organs.
Both norepinephrine and dopamine are the first-line
vasopressor agents to correct hypotension in septic shock.
Both norepinephrine and dopamine can increase blood
pressure in shock states, although norepinephrine seems
to be more powerful. Dopamine may be useful in patients
with compromised cardiac function and cardiac reserve
[13], but norepinephrine is more effective than dopami-
ne in reversing hypotension in patients with septic shock.
Dopamine has also potentially detrimental effects on the
release of pituitary hormones and especially prolactin,
although the clinical relevance of these effects is still
unclear and can have unintended effects such as tachyar-
rhythmias. Dopamine has different effects based on the
doses [14].
A dose of less than 5 μg/kg/min results in vasodilation
of renal, mesenteric, and coronary districts. At a dose of
5–10 μg/kg/min, beta-1-adrenergic effects increase car-
diac contractility and heart rate. At doses about 10 μg/
kg/min, alpha-adrenergic effects lead to arterial vasocon-
striction and increase blood pressure. Its major side
effects are tachycardia and arrhythmogenesis.
The use of renal-dose dopamine in sepsis is a controver-
sial issue. In the past, low-dose dopamine was routinely
used because of the possible renal protective effects. Do-
pamine at a dose of 2–3 μg/kg/min was known to stimu-
late diuresis by increasing renal blood flow.
A meta-analysis of literature from 1966 to 2000 for
studies addressing the use of dopamine in the prevention
and/or treatment of renal dysfunction [15] concluded
that the use of low-dose dopamine for the treatment orprevention of acute renal failure was not justified on the
basis of available evidence.
Norepinephrine is a potent alpha-adrenergic agonist
with minimal beta-adrenergic agonist effects. Norepine-
phrine can successfully increase blood pressure in pa-
tients who are septic and remain hypotensive following
fluid resuscitation. Norepinephrine is effective to treat
hypotension in septic shock patients. In many studies
norepinephrine administration at doses 0.01 to 0.3 μg/
kg/min has been shown may be effective [16,17].
Martin and coll. [18] published a randomized trial
comparing norepinephrine vs dopamine. 32 volume-re-
suscitated septic patients were given either dopamine or
norepinephrine to achieve and maintain normal hemo-
dynamic and oxygen transport parameters for at least 6 h.
Dopamine administration was successful in only 31% of
patients, whereas norepinephrine administration was suc-
cessful in 93%. Of the 11 patients who did not respond to
dopamine, 10 responded when norepinephrine was added
to therapy. Serum lactate levels were decreased as well,
suggesting that norepinephrine therapy improved tissue
oxygenation.
Recently a prospective trial by Patel and coll. com-
pared dopamine to norepinephrine as the initial vaso-
pressor in fluid resuscitated 252 adult patients with
septic shock [19]. If the maximum dose of the initial
vasopressor was unable to maintain the hemodynamic
goal, then fixed dose vasopressin was added to each regi-
men. If additional vasopressor support was needed to
achieve the hemodynamic goal, then phenylephrine was
added. In this study dopamine and norepinephrine were
equally effective as initial agents as judged by 28-day
mortality rates. However, there were significantly more
cardiac arrhythmias with dopamine treatment.
The Surviving Sepsis Campaign guidelines [10] state
that there is no sufficient evidence to suggest which
agent is better as initial vasopressor in the management
of patients with septic shock.
Phenylephrine is a selective alpha-1 adrenergic receptor
agonist primarily used in anesthesia to increase blood
pressure. Although studies are limited [20], its rapid onset,
short duration, and primary vascular effects make it an
important agent in the management of sepsis-associated
hypotension; however, it should be noted that there are
concerns regarding its potential to reduce cardiac output
in certain patients.
Epinephrine is a potent α-adrenergic and β-adrenergic
agent that increases mean arterial pressure by increasing
both cardiac index and peripheral vascular tone. The pri-
mary concern regarding the use of epinephrine in septic
patients is its potential to decrease regional blood flow,
particularly in the splanchnic circulation [21].
Vasopressin infusion of 0.01 to 0.04 U/min in patients
with septic shock increases plasma vasopressin levels to
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to other etiologies, such as cardiogenic shock. Increased
vasopressin levels are associated with a reduced demand
for other vasopressors. Urinary output may increase, and
pulmonary vascular resistance may decrease. Infusions
>0.04 U/min may lead to adverse, vasoconstriction-me-
diated events [22]. Low doses of vasopressin (0.03 U/min)
may be effective in raising blood pressure in patients re-
fractory to other vasopressors and may convey other
therapeutic benefits.
Dobutamine is frequently used to treat septic shock
patients as an inotropic agent that increases cardiac out-
put, stroke index, and oxygen delivery (Do2). However,
the tendency of dobutamine to increase Do2 to supra-
normal values in critically ill patients has raised serious
questions regarding its saftey in the treatment of septic
shock. The Surviving Sepsis Campaign Guidelines [10]
recommend that a dobutamine infusion be administered
in the event of myocardial dysfunction as indicated by
elevated cardiac filling pressures and low cardiac output
The clinical benefits of corticosteroids in the treatment
of severe sepsis and septic shock remain controversial.
A systematic review of corticosteroids in the treatment
of severe sepsis and septic shock in adult patients was
recently published in which the authors discussed 17
randomized trials (2138 patients) and 3 quasi-rando-
mized trials (n = 246) of acceptable methodological qual-
ity and pooled the results in a subsequent meta-analysis
[23]. The authors concluded that corticosteroid therapy
has been used in varied doses for treating sepsis and
related syndromes for more than 50 years, but its ability
to reduce mortality rates has never been conclusively
proven. Since 1998, studies have consistently used pro-
longed low-dose corticosteroid therapy, and follow-up
analyses of this subgroup have found that such regimens
tend to reduce short-term mortality.
According to the findings of the meta-analysis, corti-
costeroids should be considered at daily doses of 200–
300 mg of hydrocortisone (or equivalent), administered
as either an intravenous bolus or continuous infusion.
Although the evidence supporting this claim was not
particularly robust, the authors nevertheless suggested
that treatment be administered at full dosage for at least
100 hours in adult patients presenting with vasopressor-
dependent septic shock.
Diagnosis
Early diagnosis and prompt treatment of intra-
abdominal infections can minimize complications
(Recommendation 1C).
Detection of complicated intra-abdominal infections is
primarily a clinical diagnosis. However, critically ill patients
may be difficult to evaluate due to distracting injuries, re-
spiratory failure, obtundation, or other comorbidities.Initially, the pain may be dull and poorly localized (vis-
ceral peritoneum) before progressing to steady, severe,
and more localized pain (parietal peritoneum).
Signs of hypotension and hypoperfusion such as lactic
acidosis, oliguria, and acute alteration of mental status
are indicative of a patient’s transition to severe sepsis.
Diffuse abdominal rigidity suggests peritonitis and
should be addressed promptly by means of aggressive
resuscitation and surgical intervention.
Plain films of the abdomen are often the first ima-
ging analyses obtained for patients presenting with intra-
abdominal infections.
Upright films are useful for identifying free air beneath
the diaphragm (most often on the right side) as an indi-
cation of perforated viscera.
The diagnostic approach to confirming the source of
abdominal infection in septic patients depends largely on
the hemodynamic stability of the patient [24].
For unstable patients who do not undergo an im-
mediate laparotomy and whose critical condition pre-
vents them from leaving the ICU for further imaging
analysis, ultrasound is the best available imaging mo-
dality (Recommendation 1B).
For stable, adult patients who do not undergo an
immediate laparotomy, computerized tomography
(CT) is the imaging modality of choice for diag-
nosing intra-abdominal infections. In children and
young adults, exposure to CT radiation is of particu-
lar concern and must be taken into consideration
(Recommendation 1B).
When patients are stable, computerized tomography
(CT) is the optimal imaging modality for assessing most
intra-abdominal conditions [24,25].
When possible, computed tomography (CT) of the ab-
domen and pelvis is the most effective means of diag-
nosing intra-abdominal infections.
The value of both CT imaging and ultrasound in the
diagnostic work-up of intra-abdominal infections has
been comprehensively studied in the context of acute
appendicitis.
In 2006, a meta-analysis by Doria et al. demonstrated
that CT imaging featured significantly higher sensitivity
and resolution than ultrasound in studies of both chil-
dren and adults with acute appendicitis [26].
However, when examining children and young adults,
clinicians must always take into account the risk of radi-
ation exposure associated with CT.
Although CT scans are very useful in a clinical setting,
children are more radiosensitive than adults and their
exposure to ionizing radiation should be minimized [27].
Recently, a single-blind, noninferiority trial, evaluated
the rate of negative (unnecessary) appendectomies fol-
lowing low-dose and standard-dose abdominal CTs in
young adults with suspected appendicitis. Low-dose CTs
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negative appendectomy rates in young adults with sus-
pected appendicitis [18]. However low-dose CTs could
not detect perforated viscera as effectively as their stan-
dard-dose counterparts.
When CT and abdominal ultrasound are not available
diagnostic options, diagnostic peritoneal lavage may be
useful for the diagnosis of complicated IAIs [24].
Acute appendicitis
The appendectomy remains the treatment of choice
for acute appendicitis. Antibiotic therapy is a safe
means of primary treatment for patients with un-
complicated acute appendicitis, but this conservative
approach is less effective in the long-term due to sig-
nificant recurrence rates. (Recommendation 1A).
Although the standard treatment for acute appen-
dicitis has historically been the appendectomy, the me-
dical community has recently seen a notable increase
in the use of antibiotic therapy as a primary means of
treatment.
Several meta-analyses have been published overviewing
a series of randomized trials comparing antibiotic therapy
to appendectomies for acute uncomplicated appendicitis
(cases without abscesses or phlegmon) [28-31].
Although non-operative, antibioitic-mediated treatments
of uncomplicated appendicitis are associated with signifi-
cantly fewer complications, more manageable pain control,
and shorter patient sick leave, this conservative approach
features high rates of recurrence and is therefore inferior
to the traditional appendectomy.
Considering that only a small number of RCTs of poor
methodological quality are currently available, well-de-
signed RCTs are required to better assess the effects of an
antibiotic-based approach in conservative treatments of
uncomplicated acute appendicitis.
Given this controversy, the appendectomy remains
the treatment of choice for acute appendicitis. Non-
operative antibiotic treatment may be used as an alterna-
tive treatment for specific patients for whom surgery is
contraindicated.
Both open and laparoscopic appendectomies are vi-
able approaches to surgical treatment of acute appen-
dicitis (Recommendation 1A).
Several randomized trials have compared the diagnos-
tic and therapeutic advantages of laparoscopic and con-
ventional open appendectomies in the treatment of acute
appendicitis.
While the trials demonstrated a reduction in wound in-
fections for the laparoscopic appendectomy group, they
also exhibited a threefold increase in intra-abdominal
abscesses.
In 2010, Sauerland et al. updated a previously published
meta-analysis comparing the diagnostic and therapeuticresults of laparoscopic and conventional open surgery
[32]. 56 studies comparing laparoscopic appendectomies
(with or without diagnostic laparoscopy) to open ap-
pendectomies for adult patients were included in the
meta-analysis. Wound infections were less likely fol-
lowing a laparoscopic appendectomy (LA) than they were
following an open appendectomy (OA), but the laparo-
scopic procedure showed an increased prevalence of
intra-abdominal abscesses. The duration of surgery was
on average 10 minutes longer for LAs that it was for open
procedures. Compared to OAs, LAs typically resulted in
less post-operative pain; on day 1 after surgery, patients
who underwent a laparoscopic procedure reported
reduced pain by 8 mm on a 100 mm visual analogue scale
compared to patients who had undergone the open pro-
cedure. Further, the overall hospital stay was reduced for
patients who underwent LAs compared to those who
underwent OAs. While the operational costs of LAs were
significantly higher, the costs associated with recovery
were substantially reduced. 7 studies of children were in-
cluded in the review, but the results did not differ sig-
nificantly from those of similar adult-focused studies.
Diagnostic laparoscopy reduced the risk of unnecessary
appendectomies, though this trend was most common in
fertile women as compared to unselected adults [33].
However, in many cases the strong predictive power of
CT and ultrasound analysis renders the diagnostic lapar-
oscopy clinically superfluous.
In 2011, Masoomi et al. used the Nationwide Inpatient
Sample Database to evaluate the clinical data of adult
patients in the United States who had undergone either
LAs or OAs for suspected acute appendicitis from 2006
to 2008 [34].
A total of 573,244 adults underwent emergency ap-
pendectomies during this 3-year period. Overall, 65.2%
of all appendectomies were performed laparoscopically.
Use of the laparoscopic approach increased 23.7% from
58.2% in 2006 to 72% in 2008. In the context of acute
non-perforated appendicitis, LAs featured lower overall
complication rates, lower in-hospital mortality rates, and
a shorter mean length of hospitalization compared to
the open procedure.
Routine use of intraoperative irrigation for appen-
dectomies does not prevent intra-abdominal abscess
formation, adds extra costs, and may be avoided
(Recommendation 2B).
Recently a retrospective review of 176 consecutive ap-
pendectomies, open (39%) and laparoscopic (61%), at a
university affiliated tertiary care facility from July 2007
to November 2008 investigated routine use of intraope-
rative irrigation for appendectomies. The results did not
show decrease in postoperative intra-abdominal abscess
with use of intraoperative irrigation. Thirteen patients
developed postoperative abscess: 11 with irrigation, two
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scess were perforated; nine with irrigation and one with-
out [35].
Patients with periappendiceal abscesses should be
treated with percutaneous image-guided drainage.
(Recommendation 1B).
Current evidence demonstrates that an interval
appendectomy is not routinely necessary following
initial non-operative treatment of complicated ap-
pendicitis. However, interval appendicectomies should
always be performed for patients with recurrent symp-
toms (Recommendation 2B).
For patients with acute appendicitis presenting with
abscesses, the optimal management strategy is somewhat
controversial.
Percutaneous drainage to address periappendiceal abs-
cesses results in fewer complications and shorter overall
hospitalization [36-38].
In 2010, a meta-analysis was published comparing con-
servative treatment (i.e., antibiotic therapy +/− percutante-
ous abscess drainage) to appendectomies in the treatment
of complicated appendicitis (cases exhibiting abscesses or
phlegmon) [39].
17 studies (16 non-randomized/retrospective and 1
non-randomized/prospective) reported clinical data for
1572 patients: 847 patients received conservative treat-
ment and 725 underwent acute appendectomies. Con-
servative treatment was associated with significantly
fewer complications, wound infections, abdominal/pelvic
abscesses, ileal/bowel obstructions, and additional follow-
up surgeries. No significant differences were found in the
overall length of hospitalization or in the duration of
intravenous antibiotic infusion. Overall, several clinical
studies demonstrated that there were significantly fewer
complications in the conservative treatment group than
there were in the appendectomy group.
The authors concluded that conservative treatment
of complicated appendicitis was associated with decrea-
sed complication rates and fewer repeat surgeries (“re-
operations”) compared to traditional appendectomies,
while both treatments featured comparable lengths of
hospitalization.
Traditional management is initially conservative fol-
lowed by interval appendectomies performed after reso-
lution of the mass.
Recently, the efficacy of interval appendicectomies has
been called into question, and there is disagreement in
the medical community regarding whether or not the
procedure is appropriate for adults with appendiceal
abscesses. The main dispute involves the recurrence and
complication rates following interval appendectomies as
well as the procedure’s ability to address underlying ma-
lignancy. The literature provides little evidence that an
interval appendicectomy is routinely necessary; findingsinstead demonstrate that the procedure is unnecessary
in 75%-90% of cases [40-42]. The results of a review by
Andersonn and Petzold [41] based primarily on retro-
spective studies supported the practice of nonsurgical
treatment without interval appendectomies in patients
with appendiceal abscesses or phlegmon. Appendiceal
abscesses or phlegmon were found in 3.8% of patients
with appendicitis. Nonsurgical treatment failed in 7.2%
of these cases, and abscess drainage was required in
19.7%. Immediate surgery was associated with higher
morbidity rates compared to nonsurgical treatment. Af-
ter successful nonsurgical treatments, malignancy and
serious benign diseases were detected in 1.2% and 0.7%
of cases, respectively, during follow-up analyses.
Following successful conservative treatment, interval
appendicectomies were only performed for patients with
recurrent symptoms. In patients over 40 years of age,
other pathological causes of right iliac masses could be
excluded by means of further investigation (colonoscopy
and computerized tomography scans).
Studies investigating interval appendectomies after con-
servative treatment of appendiceal masses are typically
retrospective in nature. The risk of recurrence of symp-
toms is only 7.2%, which suggests that appendectomies
may not be routinely necessary [29]. Due to significant
variability between studies and their retrospective natures,
additional studies are needed to confirm these findings.Diverticulitis
Patients with uncomplicated acute diverticulitis
should be treated with antibiotic therapy to address
gram-negative and anaerobic pathogens (Recommen-
dation 2C).
The routine use of antibiotics for patients with un-
complicated acute diverticulitis is a point of controversy
in the medical community.
In 2011, a systematic review was published overview-
ing antibiotic use in cases of uncomplicated diverticulitis
[43]. Relevant data regarding the use of antibiotics in
mild or uncomplicated cases of diverticulitis were sparse
and of poor methodological quality. There was no con-
crete evidence to support the routine use of antibiotics
in the treatment of uncomplicated diverticulitis.
Recently a prospective, multicenter, randomized trial
involving 10 surgical departments in Sweden and 1 in
Iceland investigated the use of antibiotic treatment in
cases of acute uncomplicated diverticulitis. Antibiotic
treatment for acute uncomplicated diverticulitis neither
accelerated recovery nor prevented complications or re-
currence [44].
However, even in the absence of evidence support-
ing the routine use of antibiotics for patients with un-
complicated acute diverticulitis, we recommend adequate
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Mild cases of uncomplicated acute diverticulitis should
be treated in an outpatient setting. Outpatient treatment
of uncomplicated acute diverticulitis depends on the
condition and compliance of the patient as well as his or
her availability for follow-up analysis. The treatment
involves orally administered antibiotics to combat gram-
negative and anaerobic bacteria. If symptoms persist or
worsen, the patient should be admitted for more aggres-
sive inpatient treatment.
Hospitalized patients with uncomplicated acute diver-
ticulitis should be treated with intravenous fluids and
antibiotic infusion.
The clinical value of antibiotics in the treatment of
acute uncomplicated left-sided diverticulitis is poorly un-
derstood by the medical community and therefore me-
rits further study.
The grade and stage of diverticulitis are determined by
clinical severity and Hinchey classification of disease,
and used to identify patents likely to fail medical man-
agement or require surgery. Hinchey's classification pro-
vides a means of consistent classification of severity of
disease for clinical description and decision making. Per-
foration with operative findings of purulent peritonitis
corresponds to Hinchey stage III, and feculent peritonitis
to Hinchey stage IV. Stage I and Stage II refer to inflam-
matory phlegmon and paracolic abscesses [45].
Systemic antibiotic treatment alone is usually the
most appropriate treatment for patients with small
(< 4 cm in diameter) diverticular abscesses; image-
guided (ultrasound- or CT-guided) percutaneous drai-
nage is suggested for patients with large diverticular
abscesses (> 4 cm in diameter) (Recommendation 2B).
For patients with diverticulitis complicated by peridi-
verticular abscesses, the size of an abscess is an import-
ant factor in determining the proper course of action
and in deciding whether or not percutaneous drainage is
the optimal approach [46].
Patients with small pericolic abscesses (< 4 cm in diam-
eter) without generalized peritonitis (Hinchey Stage 1) can
be treated conservatively with bowel rest and broad-
spectrum antibiotics [47].
For patients with peridiverticular abscesses larger than
4 cm in diameter, observational studies indicate that CT-
guided percutaneous drainage is the treatment of choice
[48-51].
Recommendations for elective sigmoid colectomy
following recovery from acute diverticulitis should be
made on a case-by-case basis (Recommendation 1C).
The role of prophylactic surgery following conservatively
managed diverticulitis remains unclear and controversial.
Although elective resection is often recommended af-
ter single episodes of complicated acute diverticulits thatwere resolved with conservative treatment, such an inva-
sive procedure following a favorable response to nonin-
vasive methods has serious implications and should be
made on an individual basis [52-55].
Acute diverticulitis has a low rate of recurrence and
rarely progresses to more serious complications, and as
such, elective surgery to prevent recurrence and develop-
ment of further complications should be used sparingly.
To investigate recurrence rates and post-operative
complications following conservatively managed diver-
ticulitis, Eglinton et al. retrospectively analyzed clinical
data from all patients with diverticulitis admitted to their
department from 1997 to 2002 [56]. After an initial epi-
sode of uncomplicated diverticulitis, only 5% of patients
went on to develop the complicated form of the disease.
Complicated diverticulitis recurred in 24% of patients,
compared to a recurrence rate of 23.4% in those with
uncomplicated diverticulitis. Recurrence typically occur-
red within 12 months of the initial episode.
Recently, Makela et al. published a review of 977 pa-
tients admitted for acute diverticulitis during a 20-year
period [57]. The authors found that even with 2 or more
previous admissions for acute diverticulitis, sigmoid re-
section remained unjustifiably excessive.
Elective surgery is recommended for patients with
pelvic abscesses treated by means of percutaneous
drainage due to the poor long-term outcomes of
conservative treatment. However, minor mesocolic
abscesses that typically resolve when treated con-
servatively are not always grounds for surgical inter-
vention (Recommendation 1B).
Given the poor outcomes of pelvic abscesses asso-
ciated with acute left-sided colonic diverticulitis, percu-
taneous drainage followed by secondary colectomy is
recommended [58].
In the event of a colectomy performed to address
diverticular disease, a laparoscopic approach is ap-
propriate for select patients (Recommendation 1B).
Laparoscopic colectomies may have some advanta-
ges over open colectomies, including less post-operative
pain, fewer cosmetic considerations, and a shorter average
length of hospitalization. However, there appears to be no
significant difference in early or late complication rates
between the laparoscopic and open procedures [59,60].
The cost and outcome of the laparoscopic approach
are both comparable to those of the open resection [61].
Laparoscopic surgery is recommended for elderly pa-
tients [62] and appears to be safe for select patients with
complicated diverticulitis [63].
Emergency surgery is required for patients with
acute diverticulitis associated with diffuse peritonitis
as well as for patients with acute diverticulitis whose
initial non-operative management has failed (Recom-
mendation 1B).
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severe acute diverticulitis with generalized, purulent, or
fecal peritonitis as well as for patients with poor prog-
nostic criteria. In the event of diffuse peritonitis, resec-
tion with primary anastomosis and peritoneal lavage is a
suitable approach for patients with promising prognostic
criteria or for those whose non-operative management
of acute diverticulitis has failed.
Hartmann’s procedure has historically been the stand-
ard treatment for complicated acute diverticulitis [64].
However, bowel reconstruction following Hartmann’s
procedure requires additional surgeries, which many pa-
tients cannot undergo due to complicated medical con-
ditions; therefore, many of these patients remain with
permanent stoma [65].
The optimal approach for treating left colonic per-
foration is a one-stage procedure involving primary
anastomosis.
In an emergency setting, intraoperative lavage of the
colon and primary anastomosis are safe procedures for
addressing complicated diverticulitis, though Hartmann’s
procedure is still recommended for cases of diffuse or fe-
cal peritonitis, immunocompromised patients, or patients
experiencing septic shock and multiorgan failure [66].
Many studies have demonstrated that, for select pa-
tients, primary anastamosis can be safely performed in
the presence of localized or diffuse peritonitis [67].
Primary anastomosis is not recommended for patients
in high-risk categories [67-73].
In 2010, Tabbara et al. reviewed the medical records of
194 patients with complicated acute diverticulitis from
1996 to 2006 who required a colectomy within 48 hours
of hospital admission [74].
The independent criteria predictive of eventual resec-
tion with primary anastomosis included the following:
age less than 55 years, period between hospital admission
and surgery lasting longer than 4 hours, and a Hinchey
score of I or II.
There were patients featuring many of these indicators
of primary anastomosis who instead underwent fecal di-
version. The conditions and characteristics of these
patients were comparable to those of the primary anasto-
mosis patients, yet the former group experienced poorer
clinical outcomes than the latter.
In the event of either intraoperative difficulty or extra-
peritoneal anastomosis, a diverting loop ileostomy follow-
ing resection and primary anastomosis ,may suggested for
high-risk patients who are hemodynamically stable; in this
case, high risk is defined by immunosuppression, fecal
peritonitis, and/or ASA grade IV [71].
Masoomi et al. [75] using the National Inpatient Sam-
ple database, examined the clinical data of patients who
underwent an urgent open colorectal resection (sigmoi-
dectomy or anterior resection) for acute diverticulitisfrom 2002 to 2007 in the United States. A total of
99,259 patients underwent urgent surgery for acute di-
verticulitis during these years [Primary anastomosis with-
out diversion: 39.3%; Hartman's procedure (HP): 57.3%
and primary anastomosis with proximal diversion (PAD):
3.4%]. The overall complication rate was lower in the PAD
group compared with the HP group (PAD: 39.06% vs. HP:
40.84%; p = 0.04). Patients in the HP group had a shorter
mean length of stay (12.5 vs.14.4 days, p < 0.001) and
lower mean hospital costs (USD 65,037 vs. USD 73,440,
p < 0.01) compared with the PAD group. Mortality was
higher in the HP group (4.82 vs. 3.99%, p = 0.03).
PAD improved outcomes compared with HP, and
should be considered in patients who are deemed candi-
dates for two-stage operations for acute diverticulitis.
Laparoscopic peritoneal lavage with placement of
drainage tubes is a safe approach for cases of perfo-
rated diverticulitis (Recommendation 2B).
Several case series and prospective studies have de-
monstrated that laparoscopic peritoneal lavage is a safe
alternative to conventional management in the treat-
ment of perforated diverticulitis with diffuse purulent
peritonitis [76-79].
Recently a retrospective population study used an Irish
national database to identify patients acutely admitted
with diverticulitis, was published. Demographics, proce-
dures, comorbidities, and outcomes were obtained for
the years 1995 to 2008 [80].
Two thousand four hundred fifty-five patients under-
went surgery for diverticulitis, of whom 427 underwent
laparoscopic lavage. Patients selected for laparoscopic
lavage had lower mortality (4.0% vs 10.4%, p < 0.001),
complications (14.1% vs 25.0%, p < 0.001), and length of
stay (10 days vs 20 days, p < 0.001) than those requiring
laparotomy/resection. Patients older than 65 years were
more likely to die (OR 4.1, p < 0.001), as were those with
connective tissue disease (OR 7.3, p < 0.05) or chronic
kidney disease (OR 8.0, p < 0.001).
Colonic carcinoma perforation
Patients with perforated colonic carcinoma represent the
highest risk cases of colonic perforation [81].
Treatments for perforated colonic carcinoma should
both stabilize the emergency condition of the perito-
nitis and fulfil the technical objectives of oncological
intervention (Recommendation 1B).
Treating perforated colorectal cancer is a complicated
procedure and the prognosis is rarely straightforward.
Colorectal cancer-induced perforation is considered an
advanced stage disease due to the potential for periton-
eal dissemination of tumor cells throughout the site of
perforation [82].
The stage of illness, proximity of the perforation to the
tumor, and the number of metastatic lymph nodes are
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free survival rates [83].
Hartmann's procedure has been widely accepted as an
effective means of treating carcinoma of the left colon
(with adequate R0 resection) in certain emergency sce-
narios [84].
A diverting ileostomy is recommended when anasto-
mosis is performed for high-risk patients.
Colonic perforation following colonoscopy
Early detection and prompt treatment are essential
in optimizing the treatment of colonic post-colonos-
copy perforations. Patients presenting with such
perforations should undergo immediate surgical inter-
vention, which typically involves primary repair or re-
section (Recommendation 1B).
Recently, the frequency of colonic perforation has in-
creased due to routinely performed advanced therapeu-
tic endoscopy.
Over the last decade, many advancements have been
streamlined to better address these perforations, yet there
are no definitive guidelines for their optimal management
[85].
Choosing a conservative or surgical approach depends
on a variety of clinical factors [86].
Conservative management is typically used to treat
patients in stable clinical condition without any signs of
peritonitis. In published literature, fewer than 20% of
patients with colonoscopy-related perforations were suc-
cessfully treated with a non-surgical approach [87-89].
Although select patients may be responsive to non-
operative therapy, most cases warrant prompt surgical
intervention to minimize the extent of intraperitoneal
contamination, thereby facilitating a single-step proced-
ure that will likely reduce post-operative complications
[88].
Further, timely intervention (shortened timeframe bet-
ween perforation and treatment) results in improved pa-
tient outcome [90-92].
An early laparoscopic approach is a safe and effec-
tive treatment for colonoscopy-related colonic perfo-
ration (Recommendation 1C).
Laparoscopic surgery is a prudent compromise that
minimizes the risks of invasive surgery as well as those
of insufficiently aggressive non-operative therapy [93,94].
If the area of perforation cannot be localized laparo-
scopically, the surgeon should begin with a laparotomy
before proceeding further [95].
Post-traumatic bowel injuries
The time between incidence and surgery is a signifi-
cant determinant of morbidity in patients with injuries
to visceral lumens (Hollow Viscus Injuries, HVIs). An
expeditious diagnosis and prompt surgical interventionare recommended to improve the prognosis of patients
presenting with HVIs (Recommendation 1C).
Hollow Viscus Injuries (HVIs) are associated with sig-
nificant rates of morbidity and mortality. HVIs can oc-
cur by means of penetrating injury or blunt trauma, but
they are less common in patients who have experienced
blunt trauma than they are in those who have suffered a
penetrating injury. In patients who have experienced
blunt trauma, an accurate and timely diagnosis is often a
difficult undertaking.
Several mechanisms of bowel injury have been docu-
mented in the wake of blunt abdominal trauma. The
most common injury is the posterior crushing of the
bowel segment between the seat belt and vertebra or
pelvis. It results in local lacerations of the bowel wall,
mural and mesenteric hematomas, transection of the
bowel, localized devascularization, and full-thickness con-
tusions. Devitalization of the areas of contusion may sub-
sequently result in late perforation.
An important determinant of morbidity in patients
with HVIs appears to be the interim time between injury
and surgery. Only expeditious evaluation and prompt
surgical action can improve the prognosis of these pa-
tients [96].
Older age, elevated Abdominal Abbreviated Injury
Scores, significant extra-abdominal injuries, and delays
exceeding 5 hours between admission and laparotomy
were identified as significant risk factors predictive of
patient mortality [97].
Colonic non-destructive injuries should be primar-
ily repaired. Although Delayed Anastomosis (DA) is
suggested for patients with Destructive Colon In-
juries (DCI) who must undergo a Damage Control
Laparotomy (CDL), this strategy is not suggested for
high risk patients (Recommendation 2C).
Management pathway of colonic injury has been
evolving over last three decades. There has been gen-
eral agreement that injury location does not affect the
outcome.
Sharp and Coll. stratified 469 consecutive patients with
full thickness penetrating colon injuries for 13 years
by age, injury location and mechanism, and severity
of shock.
314 (67%) patients underwent primary repair and 155
(33%) underwent resection. Most injuries involved the
transverse colon (39%), followed by the ascending colon
(26%), the descending colon (21%), and the sigmoid
colon (14%). Overall, there were 13 suture line failures
(3%) and 72 abscesses (15%). Most suture line failures
involved injuries to the descending colon (p = 0.06),
whereas most abscesses followed injuries to the ascending
colon (p = 0.37). Injury location did not affect morbidity
or mortality after penetrating colon injuries. For destructive
injuries, operative decisions based on a defined algorithm
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morbidity and mortality rate and simplifies management
[98].
Colon injuries in the context of a Damage Control
Laparotomy (DCL) are associated with high complica-
tion rates and an increased incidence of leakage [99].
Performing a Delayed Anastomosis (DA) during DCL
for patients with Destructive Colon Injuries (DCI) who
require surgical resection is an effective approach with
complication rates comparable to those of conventional
laparotomy and primary anastomosis and/or standard
colostomy. However, in the event of extensive damage
with vascular and visceral involvement, the surgical out-
come depends largely on the damage control strategy.
Hollow-organ injury following penetrating trauma
should be transiently managed with suture ligation, sta-
ples, or simple suturing of the proximal and distal ends
of the affected organ, while more definitive repairs (such
as anastomosis, reconstruction, and colostomy) are ty-
pically deferred to later procedures [100-102]. Small
bowel or colonic perforations are repaired with sutured
closure. If the bowel requires resection and anastomosis,
these steps are implemented at a later time and are not
performed during initial management; this stepwise ap-
proach allows for better control of intestinal leakage
without prolonging surgical time or increasing physio-
logical stress. While the colostomy is a relatively quick
procedure, it is not always recommended given that,
during reanimation, the already edematous abdominal
wall often swells to an even greater size, and the intes-
tinal loop that is used to create the stoma may become
necrotic due to hindered blood supply. Further, these
circumstances can substantially prolong surgical time
[100-102].
In 2011, Ordonez et al. performed a retrospective re-
view of patients with penetrating DCI. The authors con-
cluded that DAs should be performed for all patients
presenting with DCI who undergo DCL; however, DAs
are not recommended for patients with recurrent intra-
abdominal abscesses, severe bowel wall edema and in-
flammation, or persistent metabolic acidosis. In these
patients, a colostomy is a more appropriate alternative
[103].
In 2011 Burlew et al. [104] reviewed patients requiring
an open abdomen after trauma from January 1, 2002 to
December 31, 2007. Type of bowel repair was stratified
as immediate repair, immediate anastomosis, delayed
anastomosis, stoma and a combination.
During the 6-year study period, 204 patients suf-
fered enteric injuries and were managed with an open
abdomen.
Enteric injuries were managed with immediate repair
(58), immediate anastomosis (15), delayed anastomosis
(96), stoma (10), and a combination (22); three patientsdied before definitive repair. Sixty-one patients suffered
intra-abdominal complications: 35 (17%) abscesses, 15
(7%) leaks, and 11 (5%) enterocutaneous fistulas. The
majority of patients with leaks had a delayed anasto-
mosis. Leak rate increased as one progresses toward the
left colon (small bowel anastomoses, 3% leak rate; right
colon, 3%; transverse colon, 20%; left colon, 45%). There
was a significant trend toward higher incidence of leak
with closure day, with closure after day 5 having a four
times higher likelihood of developing leak (3% vs. 12%,
p = 0.02).
Gastroduodenal perforation
Surgery is the treatment of choice for perforated pep-
tic ulcers. In selected cases (patients younger than
70 years of age without septic shock or peritonitis
and showing no spillage of water-soluble contrast
medium in a gastroduodenogram), non-operative ma-
nagement may be appropriate. However, if there is
no improvement of clinical condition within 24 hours
of initial non-operative treatment, the patient should
undergo surgery (Recommendation 1A).
Research has shown that surgery is the most effective
means of source control in patients with peptic ulcer
perforations [105-107].
Patients with perforated peptic ulcers may respond to
conservative treatment without surgery. Such conserva-
tive treatment consists of nasogastric aspiration, antibio-
tics, and antisecretory therapy. However, patients older
than 70 years of age with significant comorbidities, sep-
tic shock upon admission, and longstanding perforation
(> 24 hours) are associated with higher mortality rates
when non-operative treatment is attempted [107-109].
Delaying the time of surgery beyond 12 hours after the
onset of clinical symptoms reduces the efficacy of the
procedure, resulting in poorer patient outcome [110].
Simple closure with or without an omental patch is
a safe and effective procedure to address small perfo-
rated ulcers (< 2 cm) (Recommendation 1A).
In the event of large perforated ulcers, concomitant
bleeding or stricture, resectional gastroduodenal
surgery may be required. Intraoperative assessment
enables the surgeon to determine whether or not
resection is the proper course of action (Recom-
mendation 1B).
Different techniques for simple closure of perforations
have been described and documented in detail.
In 2010, Lo et al. conducted a study to determine if an
omental patch offers any clinical benefit that is not of-
fered by simple closure alone [111].
The study demonstrated that, in terms of leakage rates
and overall surgical outcome, covering the repaired per-
forated peptic ulcer with an omental patch did not con-
vey additional advantages compared to simple closure
Sartelli et al. World Journal of Emergency Surgery 2013, 8:3 Page 11 of 29
http://www.wjes.org/content/8/1/3alone. The authors of the investigation concluded that
further prospective, randomized studies were needed to
clarify the safety and feasibility of simple closure without
the support of an omental patch.
In the event of a small perforated gastroduodenal pep-
tic ulcer, no significant differences in immediate post-
operative conditions were reported when comparing
simple closure and surgery [106,111-115]
The role of resectional surgery in the treatment of
perforated peptic gastroduodenal disease is poorly un-
derstood; many reports recommend gastrectomy only in
select patients with large gastric perforations and con-
comitant bleeding or stricture [116-120].
Laparoscopic repair of perforated peptic ulcers can
be a safe and effective procedure for experienced sur-
geons (Recommendation 1A).
Aside from reduced post-operative analgesic demands,
the post-operative outcome of the laparoscopic approach
does not differ significantly from that of open surgery. In
all reported studies, patients presented with small ulcers
and received simple sutures, and many also received an
omental patch. There were no studies reporting emer-
gency laparoscopic resection or laparoscopic repair of
large ulcers [121-126].
When a pathologist is available, frozen sections
should be prepared from biopsied tissue to better as-
sess the nature of gastric perforations (Recommenda-
tion 2C).
If a patient has a curable tumor and is of a stable
clinical condition (no septic shock, localized periton-
itis, or other comorbidities) the ideal treatment is a
gastrectomy (total or sub-total) with D2 lymph-node
dissection. For patients with a curable tumor compli-
cated by poor underlying conditions, a two-stage rad-
ical gastrectomy is recommended (first step: simple
repair, second step: elective gastrectomy). By con-
trast, simple repair is recommended for patients in
poor clinical condition with non-curable tumors
(Recommendation 2C).
Surgery is the treatment of choice for cases of per-
forated gastric cancer. In most instances, gastric car-
cinoma is not suspected as the cause of perforation
prior to an emergency laparotomy, and the diagno-
sis of malignancy is often made following intra- and
post-operative examination. The treatment is intended
to both manage the emergency condition of perito-
nitis and fulfil the technical demands of oncological
intervention. Perforation alone does not significantly
affect long-term survival rates following gastrectomies
[127]; similarly, differed resections (i.e. two-stage rad-
ical gastrectomy) do not typically affect long-term re-
covery [128,129].
The presence of pre-operative shock appears to be the
most significant prognostic factor adversely affecting post-operative survival rates following surgery for perforated
gastric cancer [130].
Even in the presence of concurrent peritonitis, patients
with perforated gastric cancer should undergo gastric re-
section; the only exception to this recommendation oc-
curs when a patient is hemodynamically unstable or has
unresectable cancer [131-133].
Early detection and prompt treatment are essential
in optimizing the management of patients with post-
Endoscopic Retrograde Cholangiopancreatography (ERCP)
duodenal perforation.
Stable patients may be managed non-operatively.
The timing of surgery following failed conservative
treatment greatly influences the outcome of patients
with post-ERCP duodenal perforation (Recommenda-
tion 2C).
The use of ERCP has transitioned from a diagnostic
tool to a primarily therapeutic intervention in the treat-
ment of pancreaticobiliary disorders. Several studies
[134-137] have reported an elevated rate of ERCP-re-
lated perforation, increasing from 0.3% to 1.0%. Duo-
denal perforations may be retroperitoneal (typically in
the periampullary region following sphincterotomy) or
intraperitoneal (typically in the lateral wall following ad-
jacent endoscope passage). Intraperitoneal perforations
are often large, and affected patients may require imme-
diate surgery [138].
Diagnoses of nosocomial, procedure-related perfora-
tions are made by evaluating clinical findings, particu-
larly radiographic imaging with contrast examinations
(preferably CT). The presence of retroperitoneal air upon
CT analysis does not linearly correlate with the severity of
the condition or the need for surgery [139,140].
If there is any suspicion of perforation, the surgeon
must promptly diagnose the patient and immediately ini-
tiate systemic support, including broad-spectrum anti-
biotics and intravenous resuscitation. Following clinical
and radiographic examination, the mechanism, site, and
extent of injury should be taken into account when
selecting a conservative or surgical approach [141].
Despite extensive retroperitoneal air observed in
CT analysis, successful non-operative management of
sphincterotomy-related retroperitoneal perforations is
possible, provided that the patient remains stable
[142,143]. In contrast, if a patient develops abdominal
pain, becomes febrile, or appears critically ill, surgical
exploration should be considered for repair or drain-
age, especially in the case of elderly or chronically ill
patients who are less able to withstand physiological
stress.
Early surgical intervention often facilitates ensuing
primary repair strategies, similar in principle to closure
of duodenal perforations secondary to duodenal ulcers.
Delayed repair following failed non-operative treatment
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and drainage without repair of the actual perforation.
Several novel methods of managing ERCP-induced
perforation have been reported in recent literature
[143,144]. Some patients have been managed success-
fully with an endoclipping device; however, this procedure
is somewhat precarious given that adequate closure
requires inclusion of the submucosal layer of the bowel
wall, which clips cannot reliably ensure. Patients must be
carefully selected for this procedure; the clipping method
is only appropriate for patients who meet the criteria for
conservative management (such as the absence of peri-
toneal signs) and who present with small, well-defined
perforations detected without delay. The majority of pan-
creaticobiliary and duodenal perforations (70%) secondary
to periampullary endoscopic interventions can be treated
non-operatively [144] by means of nasogastric drainage,
antibiotic coverage and nutritional support.
Small bowel perforations
Jejunoileal perforations are a relatively uncommon source
of peritonitis in Western countries compared to less de-
veloped regions where such intestinal perforations are a
frequent contributor to high morbidity and mortality rates
[145,146].
Although prompt surgery correlates with better clin-
ical outcomes, there is widespread disagreement among
the medical community regarding the proper surgical
course of action; surgeons advocate a wide array of pro-
cedures, including simple closure, wedge excision or seg-
mental resection and anastomosis, ileostomy, and side-
to-side ileo-transverse anastomosis following primary
perforation repair.
Surgery is the treatment of choice for patients with
small bowel perforations (Recommendation 1A).
In the event of small perforations, primary repair is
recommended. However, when resection is required,
subsequent anastomosis has not been shown to re-
duce post-operative morbidity and mortality rates.
(Recommendation 2B).
Further, only treatment centers with surgeons who
are experienced in laparoscopic procedures should uti-
lize the laparoscopic approach (Recommendation 2C).
Primary repair of perforated bowels is preferable to re-
section and anastomosis due to lower complication rates,
although it should be noted that the optimal outcome in
these cases may be attributable to the limited tissue injury
of minor perforations [145,146].
Patients with malignant lesions, necrotic bowels, per-
forations associated with mesenteric vascular injuries, or
multiple contiguous perforations should not undergo
primary repair [147].
During resection, the entire diseased segment is excised,
leaving healthy, well perfused ends for anastomosis. Thetechnique used for the enteroenterostomy (stapled or
hand-sewn) seems to have little impact on the anasto-
motic complication rate.
Primary bowel anastomosis must be approached cau-
tiously in the presence of gross purulent or feculent peri-
tonitis due to high rates of serious complications [146].
While laparoscopic management of small bowel per-
forations was extensively reported in published litera-
ture, there were no studies comparing laparoscopy to
open surgery [147].
Among small bowel perforations, typhoid ileal perfor-
ation remains a serious complication of typhoid enteritis
in many tropical countries, with mortality rates as high
as 20-40% [148]. Furthermore, the increased incidence
of S. typhi infections in patients with Acquired Immuno-
deficiency Syndrome (AIDS) raises the possibility of re-
surgent typhoid fever in the developed world [149].
No meta-analyses have been published on the subject
of typhoid ileal perforation. In a recent prospective
study, 53 consecutive patients with typhoid perforation
were surgically treated; the morbidity rate for this series
of procedures was 49.1%, and the most common post-
operative complications included wound infection, wound
dehiscence, burst abdomen, residual intra-abdominal abs-
cesses, and enterocutaneous fistulae. The mortality rate
was 15.1% and was significantly affected by the presence
of multiple perforations, severe peritoneal contamination,
and burst abdomen (p value < 0.05, odds ratio > 1) [150].
The morbidity and mortality rates do not depend on
the surgical technique, but rather on the general status
of the patient, the virulence of the pathogens, and the
duration and character of disease evolution preceding
surgical treatment. It is therefore important to provide
attentive pre-operative management, including aggres-
sive resuscitation by means of intravenous hydration and
adequate antibiotic coverage. During surgery, thorough
abdominal lavage is important in cases of serious ab-
dominal suppuration [151]. Surgical treatment includes
simple closure of the perforation, ileal resection, and
side-to-side ileo-transverse colostomy or diverting ileos-
tomy [148,152,153].
Primary repair should be performed for patients with
minor symptoms and with perioperative findings of min-
imal fecal contamination of the peritoneal cavity. In the
event of enteric perforation, early repair is typically more
effective than a temporary ileostomy given that repair is
more cost effective and is free of ileostomy-related com-
plications. However, in delayed cases, there can be se-
vere inflammation and edema of the bowel, resulting in
friable tissue that complicates handling and suturing of
the bowel. Primary closure of the perforation is therefore
likely to leak, which is the etiological basis of the high
incidence of fecal peritonitis and fecal fistulae associated
with the procedure. Surgeons should perform a protective
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rates in the immediate term. The ileostomy serves to di-
vert, decompress, and exteriorize, and in doing so, appears
to have lower overall morbidity and mortality rates than
other surgical procedures. The ileostomy is particularly
useful for patients in critical condition presenting late in
the course of illness when it often proves to be a life sav-
ing procedure.
Acute cholecystitis
A laparoscopic cholecystectomy is a safe and effec-
tive treatment for acute cholecystitis. (Recommen-
dation 1A).
The laparoscopic versus open cholecystectomy debate
has been extensively investigated. Beginning in the early
1990s, techniques for laparoscopic treatment of the
acutely inflamed gallbladder were streamlined and today
the laparoscopic cholecystectomy is employed worldwide
to treat acute cholecystitis.
Many prospective trials have demonstrated that the
laparoscopic cholecystectomy is a safe and effective treat-
ment for acute cholecystitis [154-158].
An early laparoscopic cholecystectomy is a safe
treatment for acute cholecystitis and generally re-
sults in shorter recovery time and hospitalization
compared to delayed laparoscopic cholecystectomies.
(Recommendation 1A).
Timing is perhaps the most important factor in the sur-
gical treatment of acute gallstone cholecystitis (AGC).
Evidence from published literature [159-162] demon-
strates that, compared to delayed laparoscopic cholecyst-
ectomies, early laparoscopic cholecystectomies performed
to treat acute cholecystitis reduce both recurrence rates
and the overall length of hospital stay. A promptly per-
formed laparoscopic cholecystectomy is therefore the
most cost-effective means of treating acute cholecystitis.
In recent years, the medical community has debated
the possible risk factors predictive of perioperative con-
version to an open cholecystectomy from a laparoscopic
approach in cases of acute cholecystitis [163,164].
Systematic evaluation of risk factors for laparoscopic
to open conversion during cholecystectomies in patients
with acute cholecystitis may help predict procedural
difficulties and optimize surgical strategies of high-risk
cases.
A delayed laparoscopic cholecystectomy is perhaps the
most significant risk factor predictive of eventual laparo-
scopic to open conversion during a cholecystectomy in
cases of acute cholecystitis [165].
In 2011, researchers published an analysis of patients
undergoing urgent laparoscopic cholecystectomies (LCs)
for acute cholecystitis based on the prospective database
of the Swiss Association of Laparoscopic and Thoracos-
copic Surgery [166]. The patients were grouped accordingto the time lapsed between hospital admission and laparo-
scopic cholecystectomy (admission day: d0, subsequent
days of hospitalization: d1, d2, d3, d4/5, d ≥ 6). Delaying
LC resulted in the following shifts in patient outcome: sig-
nificantly higher conversion rates (increasing from 11.9%
at d0 to 27.9% at d ≥ 6, P < 0.001), increased postoperative
complications (increasing from 5.7% to 13%, P < 0.001),
elevated repeat operation rates (increasing from 0.9% to
3%, P = 0.007), and significantly longer postoperative hos-
pitalization (P < 0.001).
Percutaneous cholecystostomy can be used to safely
and effectively treat acute cholecystitis patients who
are ineligible for open surgery. Whenever possible,
percutaneous cholecystostomies should be followed
by laparoscopic cholecystectomies (Recommenda-
tion 2C).
No randomized studies have been published that com-
pare the clinical outcomes of percutaneous and trad-
itional cholecystostomies. It is not currently possible to
make definitive recommendations regarding percutan-
eous cholecystostomies (PC) or traditional cholecyst-
ectomies in elderly or critically ill patients with acute
cholecystitis.
Whenever possible, percutaneous cholecystostomies
should be followed by laparoscopic cholecystectomies.
A literature database search was performed on the
subject of percutaneous cholecystostomies in the elderly
population [167].
Successful intervention was observed in 85.6% of
patients with acute cholecystitis. A total of 40% of the
patients treated with PC were later cholecystectomized,
resulting in a mortality rate of 1.96%. The overall mor-
tality rate of the procedure was 0.36%, but 30-day mor-
tality rates were 15.4% in patients treated with PC and
4.5% in those treated with a traditional cholecystectomy
(P < 0.001).
Recently, several studies have confirmed the effects
of cholecystostomies in critically ill patients [168],
elderly patients [169], and surgically high-risk patients
[170-174].
Early diagnosis of gallbladder perforation and
immediate surgical intervention may substantially
decrease morbidity and mortality rates (Recommen-
dation 1C).
Gallbladder perforation is an unusual form of gallblad-
der disease. Early diagnosis of gallbladder perforation
and immediate surgical intervention are of utmost import-
ance in decreasing morbidity and mortality rates asso-
ciated with this condition.
Perforation is rarely diagnosed pre-operatively. Delayed
surgical intervention is associated with elevated morbidity
and mortality rates, increased likelihood of ICU ad-
mission, and prolonged post-operative hospitalization
[175-179].
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Ascending cholangitis is a life-threatening condition that
must be treated in a timely manner.
Early treatment, which includes appropriate anti-
biotic coverage, hydratation, and biliary decompres-
sion, is of utmost importance in the management of
acute cholangitis (Recommendation 1A).
The appropriatness of biliary drainage in patients with
acute cholangitis depends on specific clinical findings,
and this procedure may be secondary to a previous failed
treatment.
Cholangitis varies greatly in severity, ranging from a
mild form requiring parenteral antibiotics to severe or
suppurative cholangitis, which requires early drainage of
the biliary tree to prevent further complications [180].
Retrospective studies have shown that, 20–30 years ago,
when biliary drainage was not available, the mortality rate
of conservatively treated acute cholangitis was extremely
high [181].
Given that emergency biliary drainage in patients with
acute cholangitis is not always necessary or feasible, it is
very important that surgeons promptly and effectively
triage patients, distinguishing those who require this ur-
gent procedure from those who do not.
In 2001, Hui et al. [182] published a prospective study
investigating predictive criteria for emergency biliary de-
compression for 142 patients with acute cholangitis.
Emergency ERCP was associated with fever, a maximum
heart rate exceeding 100 beats per minute, albumin less
than 30 g/L, bilirubin greater than 50 μmol/L, and pro-
thrombin time exceeding 14 seconds.
There are 3 common methods used to perform biliary
drainage: endoscopic drainage, percutaneous transhepa-
tic drainage, and open drainage.
Endoscopic drainage of the biliary tree is safer
and more effective than open drainage (Recommen-
dation A).
Endoscopic biliary drainage is a well-established means
of biliary decompression for patients with acute cholan-
gitis caused by malignant or benign biliary disease and
associated biliary obstruction [183,184].
Many retrospective case-series studies have also de-
monstrated the efficacy of percutaneous transhepatic
drainage.
Endoscopic modalities of biliary drainage are cur-
rently favored over percutaneous procedures due to
reduced complication rates. There are currently no
RCTs comparing endoscopic and percutaneous drain-
age. (Recommendation 2C).
Currently, only retrospective studies have been pub-
lished comparing the safety and effectiveness of endo-
scopic and percutaneous transhepatic biliary drainage in
the treatment of acute obstructive suppurative cholan-
gitis. These reports confirmed the clinical efficacy ofendoscopic drainage as well as its ability to facilitate sub-
sequent endoscopic or surgical intervention [185].
Open drainage should only be performed for
patients for whom endoscopic or percutaneous trans-
hepatic drainage has failed or is otherwise contrain-
dicated (Recommendation 2C).
Given the shortened length of hospitalization and the
rarity of serious complications such as intraperitoneal
hemorrhage and biliary peritonitis, endoscopic drainage
is preferred to open drainage [186-189].Post-operative intra-abdominal infections
Post-operative peritonitis can be a life-threatening com-
plication of abdominal surgery associated with high rates
of organ failure and mortality. Treating patients with
post-operative peritonitis requires supportive therapy of
organ dysfunction, source control of infection via sur-
gery and/or drainage, and intensive antimicrobial ther-
apy [190].
Treatment recommendations are of little value given
that randomized clinical trials are extremely difficult to
perform for this particular pathology, and consequently,
little relevant literature is available on the subject.
Percutaneous drainage is the optimal means of
treating post-operative localized intra-abdominal abs-
cesses when there are no signs of generalized periton-
itis (Recommendation 2C).
Several retrospective studies in the fields of surgery
and radiology have documented the effectiveness of per-
cutaneous drainage in the treatment of post-operative
localized intra-abdominal abscesses [191-193].
Source control should be initiated as promptly as
possible following detection and diagnosis of post-
operative intra-abdominal peritonitis. Ineffective con-
trol of the septic source is associated with significantly
elevated mortality rates (Recommendation 1C).
Inability to control the septic source is associated with
significant increases in patient mortality.
Organ failure and/or subsequent re-laparotomies that
have been delayed for more than 24 hours both result in
higher rates of mortality for patients affected by post-
operative intra-abdominal infections [194].
Physical and laboratory tests are of limited value in
diagnosing abdominal sepsis. CT scans typically offer the
greatest diagnostic accuracy. Early re-laparotomies appear
to be the most effective means of treating post-operative
peritonitis [195].Re-laparotomy strategy
In certain instances infection can lead to an excessive
immune response and sepsis may progress to severe
sepsis, septic shock, or multiple organ dysfunction syn-
drome (MODS).
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septic shock and will likely experience increased compli-
cation and mortality rates [196].
These patients benefit from aggressive surgical treat-
ment, prompt intervention, and successive follow-up
surgeries (“re-operations”) to better control MODS trig-
gered by the ongoing intra-abdominal infection [197].
Deciding if and when to perform a re-laparotomy in
cases of secondary peritonitis is largely subjective and
based on professional experience. Factors indicative of
progressive or persistent organ failure during early post-
operative follow-up analysis are the best indicators of
ongoing infection [198].
Three methods are currently employed for local mech-
anical management of abdominal sepsis following an ini-
tial laparotomy:
(1) Open abdomen
(2) Planned re-laparotomy
(3) On-demand re-laparotomy
Given the procedure’s ability to streamline health-
care resources, reduce overall medical costs, and
prevent the need for further re-laparotomies, the on-
demand re-laparotomy is recommended for patients
with severe peritonitis. (Recommendation 1A).
In 2007, van Ruler et al. [199] published a randomized,
clinical study comparing planned and on-demand re-
laparotomy strategies for patients with severe peritonitis.
In this trial, a total of 232 patients with severe intra-
abdominal infections were randomized (116 planned and
116 on-demand).
In the planned re-laparotomy group, procedures were
performed every 36 to 48 hours following the index la-
parotomy to inspect, drain, lavage, and perform other
necessary abdominal interventions to address residual
peritonitis or new infectious focuses.
In the on-demand re-laparotomy group, procedures
were only performed for patients who demonstrated clin-
ical deterioration or lack of improvement that was likely
attributable to persistent intra-abdominal pathology.
Patients in the on-demand re-laparotomy group did
not exhibit a significantly lower rate of adverse outcomes
compared to patients in the planned re-laparotomy
group, but they did show a substantial reduction in sub-
sequent re-laparotomies and overall healthcare costs.
The on-demand group featured a shorter median ICU
stay (7 days for on-demand group < 11 days for planned
group; P = 0.001) and a shorter median length of hospitali-
zation (27 days for on-demand group < 35 days for plan-
ned group; P = 0.008). Direct per-patient medical costs
were reduced by 23% using the on-demand approach.
Members of our Expert Panel emphasize, however,
that an on-demand strategy is not a forgone conclusionfor all patients presenting with severe secondary periton-
itis; that is, secondary peritonitis alone isn’t necessary
and sufficient to automatically preclude other alterna-
tives. The decision to implement an on-demand strategy
is based on contextual criteria and should be determined
on a case-by-case basis.
For “wait-and-see” management of on-demand pa-
tients requiring follow-up surgery, early re-laparotomies
appear to be the most effective means of treating post-
operative peritonitis and controlling the septic source
[200-202].
Organ failure and/or subsequent re-laparotomies de-
layed for more than 24 hours both correlate with higher
mortality rates for patients affected by post-operative
intra-abdominal infections [203].
Deciding whether or not to perform additional surger-
ies is context sensitive and depends on the surgeon and
on his or her professional experience; no telltale clinical
parameters are available [204,205].
The findings of a single RTC are hardly concrete, and
further studies are therefore required to better define
the optimal re-laparotomy strategy.
The open abdomen remains a viable option for
treating intra-abdominal sepsis. The benefits of main-
taining an open abdomen include ease of subsequent
exploration, control of abdominal contents, reduced
risk of intra-abdominal hypertension and abdominal
compartment syndrome, and fascial preservation to
ensure proper closure of the abdominal wall. However,
prolonged exposure of abdominal viscera can result in
additional complications, including infection, sepsis,
and fistula formation (Recommendation 1C).
The open abdomen is the most technically straight-
forward means of conducting a planned follow-up
procedure.
Open treatment was first used to manage severe intra-
abdominal infections and pancreatic necrosis [200].
However, severe complications such as evisceration, fis-
tula formation, and the development of giant incisional
hernias were frequently observed in this procedure.
Temporary closure of the abdomen may be achieved by
using gauze and large, impermeable, self-adhesive mem-
brane dressings, both absorbable and non-absorbable me-
shes, and negative pressure therapy devices.
At present, negative pressure techniques (NPT) have
become the most extensively employed means of tem-
porary closure of the abdominal wall.
In recent years, open abdomen procedures have in-
creased dramatically due to streamlined “damage control”
techniques in life-threatening conditions, recognition and
treatment of intra-abdominal hypertension and abdominal
compartment syndrome, and important clinical findings
regarding the management of severe intra-abdominal
sepsis.
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physiology of open abdomen conditions as well as the
development of new technologies for temporary abdom-
inal wall closure have improved the management and
outcome of patients undergoing this procedure [203].
Severe intra-abdominal infection is a progressive con-
dition; affected patients progress from sepsis to severe
sepsis with organ dysfunction and ultimately to septic
shock.
This stepwise progression is characterized by excessive
proinflammation, which causes vasodilation, hypoten-
sion, and myocardial depression. These effects combined
with endothelial activation and Diffused Intravascular
Coagulopathy (DIC), cause ongoing endothelial leakage,
cellular shock, and microvascular thrombosis. Out-
wardly, clinical manifestations are characterized by sep-
tic shock and progressive MOF. In this situation, a
surgeon must decide whether or not to perform a “dam-
age control” laparotomy, thereby providing prompt and
aggressive source control to curb the momentum of cres-
cendoing sepsis.
Advantages of the open abdomen include prevention
of abdominal compartment syndrome (ACS). In the
event of septic shock, massive fluid resuscitation, bowel
edema and forced closure of a non-compliant abdom-
inal wall all contribute to intra-abdominal hyperten-
sion (IAH). Elevated intra-abdominal pressure (IAP)
adversely affects the physiological processes of pulmonary,
cardiovascular, renal, splanchnic, and central nervous sys-
tems. The combination of IAH and other physiological
stressors contributes to significantly elevated morbidity
and mortality rates.
Several studies have investigated open abdomen in
the context of intra-abdominal infections, generating
great interest and optimism in the medical community
[206-209].
However, in 2007 a randomized study compared open
and closed “on-demand” management of severe periton-
itis. The study was terminated following the inclusion of
only 40 patients after acknowledging the clearly discern-
able clinical disadvantages of the open abdomen group
(55% and 30% mortality rates for open and closed proce-
dures, respectively). It should be noted that, in this
study, the open abdomen was managed exclusively with
non-absorbable polypropylene mesh and without nega-
tive pressure therapy [210].
Following stabilization of the patient, surgeons
should attempt early, definitive closure of the abdo-
men. Primary fascial closure may be possible when
there is minimal risk of excessive tension or recur-
rence of IAH (Recommendation 1C).
When early, definitive fascial closure is not possible,
progressive closure should be attempted each time the
patient returns for subsequent procedures.For patients with persistent large fascial defects, it
is suggested that surgeons implement bridging with
biological materials (Recommendation 1C).
Following stabilization of the patient, the primary ob-
jective is early and definitive closure of the abdomen to
minimize complications associated with OA [206].
For many patients, primary fascial closure may be pos-
sible within a few days of the initial operation [206].
In other patients, early definitive fascial closure may
not be possible. In these cases, surgeons should attempt
progressive closure, in which the abdomen is incrimen-
tally closed each time the patient undergoes a subse-
quent surgery.
Many methods of fascial closure have been described
in medical literature [211-216]. In many cases abdominal
closure is only partially achieved, resulting in large, de-
bilitating hernias of the abdominal wall that will eventu-
ally require complex surgical repair. In these cases,
bridging with biological mesh is recommended [217].
Antimicrobial therapy
Initial antibiotic therapy for IAIs is typically empirical in
nature because the patient needs immediate attention,
and microbiological data (culture and susceptibility re-
sults) can require up to 48 hours before they are avai-
lable for a more detailed analysis.
IAIs can be treated with either single or multiple anti-
microbial regimens depending on the range require-
ments of antimicrobial coverage.
Beta-lactam/beta-lactamase inhibitor combinations ex-
hibit in vitro activity against gram-positive, gram-nega-
tive, and anaerobic organisms [218,219] and are viable
options for empirical treatment of IAIs [218]. However,
the increasing prevalence of drug-resistant Enterobacteria-
ceae observed in community-acquired infections restricts
this regimen’s empirical use to patients who are not at risk
for these drug-resistant microorganisms [220].
In the past, Cephalosporins have often been used in
the treatment of intra-abdominal infections. Among third
generation cephalosporins, subgroups with both limited
and strong activity against Pseudomonas aeruginosa (cefe-
pime and ceftazidime) have been used in conjunction with
metronidazole to treat IAIs. Enterobacteriaceae can have
acquired resistance to both cephalosporins, while such re-
sistance is intrinsic in Enterococci [221-223].
In light of the increasing prevalence of ESBL-pro-
ducing enterobacteriaceae due to selection pressures
related to overuse of cephalosporins, routine use of these
antibiotics is strongly discouraged.
Aztreonam is a parenteral synthetic beta-lactam anti-
biotic and the first monobactam marketed for clinical
use. The drug exhibits potent in vitro activity against a
wide spectrum of gram-negative aerobic pathogens (in-
cluding Pseudomonas aeruginosa), but its routine use is
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strains, and it therefore shares the same constraints
associated with cephalosporin use.
Carbapenems offer a wide spectrum of antimicrobial
activity against gram-positive and gram-negative aerobic
and anaerobic pathogens (with the exception of MDR
resistant gram-positive cocci). For more than 2 decades,
carbapenems have been considered the agents of “last
resort” for multidrug-resistant infections caused by En-
terobacteriaceae. In the last decade, increased carbape-
nem consumption has been associated with an increased
emergence of carbapenem resistance among Enterobac-
teriacea, particularly in Klebsiella pneumoniae.
The recent and rapid spread of serine carbapenemases
in Klebsiella pneumoniae (known as Klebsiella pneumo-
niae carbapenemases or KPCs) has become an issue of
crucial importantance in hospitals worldwide [224].
Group 1 carbapenems include ertapenem, a once-
a-day carbapenem that shares the activity of imipenem
and meropenem against most species, including ex-
tended-spectrum beta-lactamase (ESBL)-producing pa-
thogens, but is not active against Pseudomonas and
Enterococcus species [225,226].
Group 2 includes imipenem/cilastatin, meropenem,
and doripenem, which share activity against non-
fermentative gram-negative bacilli. Researchers have re-
ported doripenem’s slightly elevated in vitro activity
against certain Pseudomonas strains in registrative trials
[227].
Further, given their excellent tissue penetration and
strong activity against aerobic gram-negative bacteria,
fluoroquinolones have been widely used in recent years
for treatment of IAIs. It should also be noted that all
fluoroquinolones are rapidly and almost completely
absorbed from the gastrointestinal tract.
A combination of ciprofloxacin/metronidazole has
been perhaps the most commonly used regimen for
complicated IAIs in recent years. The latest quinolone,
Moxifloxacin, has demonstrated to be active against a
wide range of aerobic gram-positive and gram-negative
species [228]. Compared to ciprofloxacin, moxifloxacin
has enhanced activity against gram-positive bacteria and
decreased activity against gram-negative bacteria [229].
Among quinolones, moxifloxacin appears to also be ef-
fective against Bacterioides fragilis, suggesting that the
drug may be equally effective without co-administered
antianaerobic agents [230-232]. However, in recent
years, the ever-increasing incidence of drug resistance
among Enterobacteriaceae and non-fermentative gram-
negative bacilli has discouraged the drug’s use in empirical
regimens.
Aminoglycosides are particularly active against aerobic
gram-negative bacteria and act synergistically against
certain gram-positive organisms. They are effective againstPseudomonas aeruginosa but are ineffective against anaer-
obic bacteria. Aminoglycosides may be suboptimal for
treatment of abscesses or intra-abdominal infections due
to their low penetration in acidic environments [233].
Tigecycline is a parenteral glycylcycline antibiotic de-
rived from minocycline. It is the first representative of
the glycylcycline class of antibacterial agents to be mar-
keted for clinical use [234,235].
While tigecycline does not feature in vitro activity
against P. aeruginosa or P. mirabilis, it remains a viable
treatment option for complicated IAIs due to its favor-
able in vitro activity against anaerobic organisms, En-
terococci, several ESBL- and carbapenemase-producing
Enterobacteriaceae, Acinetobacter species, and Stenotro-
phomonas maltophilia [236-238].
The use of tigecycline to treat IAIs is particularly use-
ful in light of its unique pharmacokinetic properties; the
drug is eliminated by active biliary secretion and is
therefore able to establish high biliary and fecal concen-
trations [239].
Cultures from the site of infection are always
recommended for patients with healthcare-associated
infections or with community-acquired infections at
risk for resistant pathogens. In these patients, the
causative pathogens and the related resistance pat-
terns are not readily predictable and therefore re-
quire further analysis (Recommendation 1C).
The results of microbiological analysis are helpful in
designing therapeutic strategies for individual patients to
customize antibiotic treatments and ensure adequate
antimicrobial coverage.
Although it has been documented that bacteriological
cultures have little impact on the course of treatment of
common conditions like appendicitis [240], in this era
of prevalent drug-resistant microorganisms involved in
both nosocomial and community-acquired infections, the
threat of resistance is a source of major concern that can-
not be ignored.
In 2010, a review was published investigating the value
of peritoneal fluid cultures in cases of appendicitis [241].
All included studies focusing on the use of intra-
peritoneal swabs were open, non-randomized, and retro-
spective; further, they featured incompletely matched
control groups and non-standardized swab collection
techniques, and therefore offered limited statistical po-
wer with which to suggest modifications of surgical
practice. Until controlled trial data of more reliable
methodological quality become available, clinicians should
continue the use of peritoneal swabs, especially for high-
risk patients.
Cultures should be taken from intra-abdominal sam-
ples during surgical or interventional drainage procedures.
Surgeons must ensure sufficient volume (a minimum of
1 mL of fluid or tissue) before sending the samples to a
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properly handles the samples so as not to damage them or
compromise their integrity.
The empirically designed antimicrobial regimen
depends on the underlying severity of infection, the
pathogens presumed to be involved, and the risk fac-
tors indicative of major resistance patterns (Recom-
mendation 1B).
Predicting the pathogens and potential resistance
patterns of a given infection begins by establishing whe-
ther the infection is community-acquired or healthcare-
associated (nosocomial).
The major pathogens involved in community-acquired
intra-abdominal infections are Enterobacteriaceae, Strep-
tococcus species, and anaerobes (especially B. fragilis).
Contrastingly, the spectrum of microorganisms in-
volved in nosocomial infections is significantly broader.
In the past 20 years, the incidence of healthcare-associated
infections caused by drug-resistant microorganisms has
risen dramatically, probably in correlation with escalating
levels of antibiotic exposure and increasing frequency of
patients with one or more predisposing conditions, in-
cluding elevated severity of illness, advanced age, de-
gree of organ dysfunction, low albumin levels, poor
nutritional status, immunodepression, presence of malig-
nancy, and other comorbidities.
Although the transmission of multidrug-resistant or-
ganisms is most frequently observed in acute care facil-
ities, all healthcare settings are affected by the emergence
of drug-resistant pathogens.
In past decades, an increased prevalence of infections
caused by antibiotic-resistant pathogens, including me-
thicillin-resistant Staphylococcus aureus, vancomycin-
resistant Enterococcus species, carbapenem-resistant
Pseudomonas aeruginosa, extended-spectrum beta-
lactamase (ESBL)-producing Escherichia coli and Klebsi-
ella species, multidrug-resistant Acinetobacter species,
and Candida species has been observed, particularly in
cases of intra-abdominal infection [242-244].
For patients with severe sepsis or septic shock, early
and properly administered empirical antimicrobial ther-
apy can have a significant impact on the outcome, inde-
pendent of the anatomical site of infection [245].
These data confirm the results of Riché et al. whose
prospective observational study involving 180 conse-
cutive patients with secondary generalized peritonitis
demonstrated a significantly higher mortality rate for
patients in septic shock (35% and 8% for patients with
and without shock, respectively) [246].
International guidelines for the management of severe
sepsis and septic shock (the Surviving Sepsis Campaign)
recommend intravenously administered antibiotics within
the first hour of onset of severe sepsis and septic shock
and the use of broad-spectrum agents with adequatepenetration of the presumed site of infection. Additionally,
the employed antimicrobial regimen should be reassessed
daily in order to optimize efficacy, prevent toxicity, mi-
nimize cost, and reduce selection pressures favoring resis-
tant strains [10].
To ensure timely and effective administration of
antimicrobial therapy for critically ill patients, clini-
cians must consider the pathophysiological and im-
munological status of the patient as well as the
pharmacokinetic properties of the employed antibio-
tics (Recommendation 1C).
In the event of abdominal sepsis, clinicians must be
aware that drug pharmacokinetics may be altered signifi-
cantly in critically ill patients due to the pathophysiology
of sepsis. The “dilution effect,” also known as the “third
spacing phenomenon,” is very important for hydrophilic
agents. Higher than standard loading doses of hydro-
philic agents such as beta-lactams, aminoglycosides, and
glycopeptides should be administered to ensure optimal
exposure at the infection site, maintaining a therapeutic
threshold that withstands the effects of renal function
[247].
For lipophilic antibiotics such as fluoroquinolones and
tetracyclines, the “dilution effect” in extracellular fluids
may be mitigated during severe sepsis by the rapid redis-
tribution of drugs to the interstitium from the intracellu-
lar compartment. Unlike observations of subtherapeutic
administration of standard-dose hydrophilic antimicro-
bials, standard dosages of lipophilic antimicrobials are
often sufficient to ensure adequate loading, even in pa-
tients with severe sepsis or septic shock [248].
Once initial loading is achieved, it is recommended that
clinicians reassess the antimicrobial regimen daily, given
that pathophysiological changes may occur that signifi-
cantly alter drug disposition in critically ill patients.
Lower-than-standard dosages of renally excreted drugs
must be administered in the presence of impaired renal
function, while higher-than-standard dosages of renally
excreted drugs may be required for optimal exposure in
patients with glomerular hyperfiltration [249].
Table 2 overviews recommended dosing regimens of the
most commonly used renally excreted antimicrobials.
The therapeutic approach undertaken by clinicians must
take into account the activity of employed antimicrobials.
Antibiotics such as quinolones, daptomycin, tigecy-
cline, aminoglycosides, polienes, and echinocandins ex-
hibit concentration-dependent activity; as such, the dose
should be administered in a once-a-day manner (or with
the lowest possible daily administrations) in order to
achieve zenithal plasma levels [249].
Beta-lactams, glycopeptides, oxazolidinones, and azoles
exhibit time-dependent activity and exert optimal bacteri-
cidal activity when drug concentrations are maintained
above the Minimum Inhibitory Concentration (MIC).
Table 2 Recommended dosing regimens (according to renal function) of the most commonly used renally excreted
antimicrobials [248]
Renal function
Antibiotic Increased Normal Moderately impaired Severely impaired
Piperacillin/tazobatam 16/2 g q24 h CI or 3.375 q6 h
EI over 4 hours
4/0.5 g q6 h 3/0.375 g q6 h 2/0.25 g q6 h
Imipenem 500 mg q4 h or 250 mg q3 h
over 3 hours CI
500 mg q6 h 250 mg q6 h 250 mg q12 h
Meropenem 1 g q6 h over 6 hours CI 500 mg q6 h 250 mg q6 h 250 mg q12 h
Ertapenem ND 1 g q24 h 1 g q24 h 500 mg q24 h
Gentamycin 9 to 10 mg/kg q24 hb 7 mg/kg q24 h 7 mg/kg q36–48 h 7 mg/kg q48–96 h
Amikacin 20 mg/kg q24 h 15 mg/kg q24 h 15 mg/kg q36–48 hb 15 mg/kg q48–96 h
Ciprofloxacin 600 mg q12 h or 400 mg q8 h 400 mg q12 h 400 mg q12 h 400 mg q24 h
Levofloxacin 500 mg q12 h 750 mg q24 h 500 mg q24 h 500 mg q48 h
Vancomycin 30 mg/kg q24 h CI 500 mg q6 h 500 mg q12 h 500 mg q24–72 h
Teicoplanin LD 12 mg/kg q12 h for 3 to
4 doses; MD 6 mg/kg q12 h
LD 12 mg/kg q12 h for 3 to 4
doses; MD 4 to 6 mg/kg q12 h
LD 12 mg/kg q12 h for 3 to 4
doses; MD 2 to 4 mg/kg q12 h
LD 12 mg/kg q12 h for 3 to 4
doses; MD 2 to 4 mg/kg q24 h
Tigecycline LD 100 mg; MD 50 mg q12 h LD 100 mg; MD 50 mg q12 h LD 100 mg; MD 50 mg q12 h LD 100 mg; MD 50 mg q12 h
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severely ill patients is related primarily to the mainten-
ance of supra-inhibitory concentrations, and therefore
multiple daily dosing may be appropriate.
For these drugs, continuous intravenous infusion en-
sures the highest steady-state concentration under the
same dosage constraints and may therefore be the most
effective means of maximizing pharmacodynamic expo-
sure [250,251].
For patients with community-acquired intra-abdo-
minal infections (CA-IAIs), agents with a narrower
spectrum of activity are preferred. However, if CA-
IAI patients have prior exposure to antibiotics or ser-
ious comorbidities requiring concurrent antibioitic
therapy, anti-ESBL-producer converage may be war-
ranted. By contrast, for patients with healthcare-
associated infections, antimicrobial regimens with
broader spectra of activity are preferred (Recommen-
dation 1B).
In the context of intra-abdominal infections, the main
resistance problem is posed by ESBL-producing Entero-
bacteriaceae, which are alarmingly prevalent in nosoco-
mial infections and frequently observed in community-
acquired infections, albeit to a lesser extent.
The Study for Monitoring Antimicrobial Resistance
Trends (SMART) program monitors the activity of an-
tibiotics against aerobic gram-negative intra-abdominal
infections. Hawser et al. reported susceptibility levels of
key intra-abdominal pathogens in Europe in 2008 and
noted that the number of viable treatment options avai-
lable for empirical treatment of intra-abdominal infec-
tions had fallen dramatically [252].
Although a variety of factors can increase the risk of
selection for ESBL producers, the most significant riskfactors include prior exposure to antibiotics (especially
third generation cephalosporins) and comorbidities re-
quiring concurrent antibiotic therapy.
In a study published by Ben-Ami et al., researchers
evaluated risk factors for non-hospitalized patients that
increased susceptibility to ESBL-producing infections;
the study compiled data from 6 treatment centers in
Europe, Asia, and North America [253].
A total of 983 patient-specific isolates were ana-
lyzed; 890 [90.5%] were Escherichia coli; 68 [6.9%] were
Klebsiella species; and 25 [2.5%] were Proteus mirabilis.
Overall, 339 [34.5%] of the observed isolates produced
ESBLs. Significant risk factors identified by multivariate
analysis included recent antibiotic exposure, residence in
long-term care facilities, recent hospitalization, and advan-
ced age greater than 65 years. Additionally, men appeared
to be more prone to these infections than women.
However, 34% of the analyzed ESBL isolates were de-
rived from patients with no recent healthcare exposure.
Bacteria producing Klebsiella pneumoniae carbapene-
mases (KPCs) are rapidly emerging as a major source
of multidrug-resistant infections worldwide. The recent
emergence of carbapenem resistance among Enterobacter-
iaceae poses a considerable threat to hospitalized patients.
In addition to hydrolyzing carbapenems, KPC-produ-
cing strains are often resistant to a variety of other an-
tibiotics, and effective treatment of these versatile and
resilient pathogens has therefore become an important
challenge for clinicians in acute care settings [254].
KPC-producing bacteria have become commonplace
in nosocomial infections, especially in patients with pre-
vious exposure to antibiotics [255].
Further, Pseudomonas aeruginosa and Acinetobacter
baumannii have exhibited alarming rates of increased
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healthcare facilities worldwide. Both species are intrin-
sically resistant to several drugs and could acquire add-
itional resistances to other important antimicrobial agents
[256].
Although no supportive data are currently available, P.
aeruginosa coverage is only generally recommended for
patients with nosocomial intra-abdominal infections, des-
pite the fact that, in certain subpopulations, an inexplic-
ably high prevalence of Pseudomonas aeruginosa has been
documented in association with community-acquired
appendicitis, which may complicate empirical antibiotic
therapy [257].
Among multidrug-resistant gram-positive bacteria, En-
terococci remain a considerable challenge.
Empirical coverage of Enterococci is not generally re-
commended for patients with community-acquired IAIs.
Studies have demonstrated that coverage against Ente-
rococci offers little therapeutic benefit for patients with
community-acquired infections [258,259].
In the context of community-acquired IAIs, antimicro-
bial therapy for Enterococci should be considered for im-
munocompromised patients, patients with valvular heart
disease or prosthetic materials, and critically ill patients
for whom empirical antimicrobial therapy has a significant
impact on clinical outcome.
Methicillin-resistant Staphylococcus aureus (MRSA) is
another multidrug-resistant gram-positive nosocomial
pathogen known to cause severe morbidity and mortality
worldwide [260].
Although community-acquired MRSA has been repor-
ted in other settings, there are no studies that have sys-
tematically documented MRSA in community-acquired
intra-abdominal infections.
Patients with nosocomial intra-abdominal infections
should not be treated empirically for MRSA unless the
patient has a history of infections by this organism or
there is reason to believe that the infection is associated
with MRSA.
Appendices 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 list recommended
antimicrobial regimens.
Empirical antifungal therapy for Candida species is
recommended for patients with nosocomial infec-
tions and for critically ill patients with community-
acquired infections. An echinocandin regimen is
recommended for critically ill patients with nosoco-
mial infections (Recommendation 1B).
Although the epidemiological profile of Candida spe-
cies has not yet been defined in the context of nosoco-
mial peritonitis, its presence is clinically significant and
is usually associated with poor prognoses.
Empirical antifungal therapy for Candida species is typ-
ically not recommended for patients with community-
acquired intra-abdominal infections, with the notableexceptions of patients recently exposed to broad-spectrum
antimicrobials and immunocompromised patients (due to
neutropenia or concurrent administration of immunosup-
pressive agents, such as glucocorticosteroids, chemothera-
peutic agents, and immunomodulators) [261].
However, considering the high mortality rate of
Candida-related peritonitis, and given the poor out-
come that could result from inadequate antimicrobial
therapy for critically ill patients, antifungal coverage
is recommended for these patients
In 2006, Montravers et al. published a retrospective,
case–control study involving critically ill patients admit-
ted to 17 French intensive care units (ICUs) [262].
The study demonstrated an increased mortality rate in
cases of nosocomial peritonitis in which fungal isolates
had been identified (48% and 28% mortality rates for fun-
gal peritonitis and control groups, respectively p < 0.01).
Upper gastrointestinal tract sites and positive identifica-
tion of Candida species were found to be independent
variables predictive of mortality for patients with nosoco-
mial peritonitis.
More recently, Montravers et al. published the results of
a prospective, non-interventional study involving 271 adult
ICU patients with invasive Candida infections who re-
ceived systemic antifungal therapy; the authors reported a
mortality rate of 38% in a prospective cohort of 93 patients
admitted to the ICU with candidal peritonitis [261].
Given the results of these studies, the inclusion of an
anticandidal drug in empirical regimens for nosocomial
IAIs seems appropriate.
The recently published Pappas IDSA guidelines for the
treatment of invasive candidiasis do not dedicate a spe-
cific section to candidal peritonitis [263]. However, the
use of echinocandins is generally recommended as a
first-line empirical treatment for critically ill patients,
while fluconazole is typically recommended for less se-
vere conditions.
Applying these trends to IAIs, the use of echinocan-
dins is recommended as a first-line treatment in cases of
severe nosocomial IAI.
Knowledge of mechanisms of secretion of antibio-
tics into bile is helpful in designing the optimal the-
rapeutic regimen for patients with biliary-related
intra-abdominal infections (Recommendation 1C).
The bacteria most often isolated in biliary infections
are Escherichia coli and Klebsiella pneumonia, gram-
negative aerobes,, as well as certain anaerobes, particu-
larly Bacteroides fragilis. Given that the pathogenicity of
Enterococci in biliary tract infections remains unclear,
specific coverage against these microorganisms is not
routinely advised [264-266].
The efficacy of antibiotics in the treatment of biliary
infections depends largely on the therapeutic level of
drug concentrations [267-271].
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microbials with effective biliary penetration to address
biliary infections. However, no clinical or experimental
evidence is available to support the recommendation
of biliary-penetrative antimicrobials for these patients.
Other important factors include the antimicrobial po-
tency of individual compounds and the effect of bile on
antibacterial activity [270].
If there are no signs of persistent leukocytosis or
fever, antimicrobial therapy for intra-abdominal
infections should be shortened for patients demon-
strating a positive response to treatment (Recom-
mendation 1C).
An antimicrobial-based approach involves both opti-
mizing empirical therapy and curbing excessive antimi-
crobial use to minimize selective pressures favoring drug
resistance [271].
Shortening the duration of antimicrobial therapy in
the treatment of intra-abdominal infections is an import-
ant strategy for optimizing patient care and reducing the
spread of antimicrobial resistance.
The optimal duration of antibiotic therapy for intra-
abdominal infections has been extensively debated.
Shorter durations of therapy have proven to be as ef-
fective as longer durations for many common infections.
A prospective, randomized, double-blind trial comparing
3- and ≥ 5-day ertapenem regimens in 111 patients with
community-acquired intra-abdominal infections repor-
ted similar cure and eradication rates (93% vs. 90% and
95% vs. 94% for 3- and > 5-day regimens, respectively)
[272].
Studies have demonstrated a low likelihood of infec-
tion recurrence or treatment failure when antimicrobial
therapy is discontinued in patients with complicated
intra-abdominal infection who no longer show signs of
infection.
Lennard et al. [273] compared post-operative out-
comes in 65 intra-abdominal sepsis patients with and
without leukocytosis and fever at the conclusion of anti-
microbial therapy. Intra-abdominal sepsis patients at risk
for post-operative infection were those who were afebrile
with persistent leukocytosis or those who remained fe-
brile after the antibiotics were discontinued.
Hedrick et al. [274] retrospectively analyzed the rela-
tionship between the duration of antibiotic therapy and
infectious complications (i.e., recurrent infection by the
same organism or renewed infectious focus at the same
anatomical site). In the study, 929 patients with intra-
abdominal infections associated with fever or leukocytosis
were categorized into quartiles on the basis of either the
total duration of antibiotic therapy or the duration of
treatment following resolution of fever and leukocytosis.
Shorter courses of antibiotics were associated with com-
parable or fewer complications than prolonged therapy.These results suggest that antimicrobial therapy to ad-
dress intra-abdominal infections should be shortened for
patients who demonstrate a positive response to treat-
ment, show no signs of persistent leukocytosis or fever,
and are able to resume an oral diet.
Conclusions
Despite advances in diagnosis, surgery, and antimicrobial
therapy, mortality rates associated with complicated
intra-abdominal infections remain exceedingly high.
WSES guidelines represent a contribution on this de-
bated topic by specialists worldwide.
Appendix 1. Antimicrobial therapy for
community-acquired extra-biliary IAIs in stable,
non-critical patients presenting with no ESBL-
associated risk factors (WSES recommendations)
Community-acquired extra-biliary IAIs
Stable, non-critical patients
No risk factors for ESBL
AMOXICILLIN/CLAVULANATE
Daily schedule: 2.2 g every 6 hours (2-hour infusion time)
OR (in the event of patients allergic to beta-lactams):
CIPROFLOXACIN
Daily schedule: 400 mg every 8 hours (30-minute
infusion time)
+
METRONIDAZOLE
Daily schedule: 500 mg every 6 hours (1-hour infusion
time)
Appendix 2. Antimicrobial therapy for
community-acquired extra-biliary IAIs in stable,
non-critical patients presenting with ESBL-
associated risk factors (WSES recommendations)
Community-acquired extra-biliary IAIs
Stable, non-critical patients
ESBL-associated risk factors
ERTAPENEM
Daily schedule: 1 g every 24 hours (2-hour infusion time)
OR
TIGECYCLINE
Daily schedule: 100 mg LD then 50 mg every 12 hours
Appendix 3. Antimicrobial therapy for
community-acquired extra-biliary IAIs in critically
ill patients presenting with no ESBL-associated
risk factors (WSES recommendations)
Community-acquired extra-biliary IAIs
Critically ill patients (≥ SEVERE SEPSIS)
No risk factors for ESBL
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Daily schedule: 8/2 g LD then 16/4 g/day via
continuous infusion or 4.5 g every 6 hours (4-hour
infusion time)
Appendix 4. Antimicrobial therapy for
community-acquired extra-biliary IAIs in critically
ill patients presenting with ESBL-associated risk
factors (WSES recommendations)
Community-acquired IAIs
Critically ill patients (≥ SEVERE SEPSIS)
ESBL-associated risk factors
MEROPENEM
Daily schedule: 500 mg every 6 hours (6-hour
infusion time)
OR
IMIPENEM
Daily schedule: 500 mg every 4 hours (3-hour
infusion time)
+/−
FLUCONAZOLE
Daily schedule: 600 mg LD then 400 mg every 24 hours
(2-hour infusion time)
Appendix 5. Antimicrobial therapy for biliary IAI
in stable, non-critical patients presenting with no
ESBL-associated risk factors (WSES
recommendations)
Community-acquired biliary IAIs
Stable, non-critical patients
No risk factors for ESBL
AMOXICILLIN/CLAVULANATE
Daily schedule: 2.2 g every 6 hours (2-hour infusion
time)
OR (in the event of patients allergic to beta-lactams)
CIPROFLOXACIN
Daily schedule: 400 mg every 8 hours (30-minute
infusion time)
+
METRONIDAZOLE
Daily schedule: 500 mg every 6 hours (1-hour infusion
time)
Appendix 6. Antimicrobial therapy for biliary IAIs
in stable, non-critical patients presenting with
ESBL-associated risk factors (WSES
recommendations)
Community-acquired biliary IAIs
Stable, non-critical patients.
Risk factors for ESBL
TIGECYCLINEDaily schedule: 100 mg LD then 50 mg every 12 hours
(2-hour infusion time)
Appendix 7. Antimicrobial therapy for biliary
IAIs in critically ill patients presenting with
no ESBL-associated risk factors (WSES
recommendations)
Community-acquired biliary IAIs
Critically ill patients (≥ SEVERE SEPSIS)
No risk factors for ESBL
PIPERACILLIN/TAZOBACTAM
Daily schedule: 8/2 g LD then 16/4 g/day via
continuous infusion or 4.5 g every 6 hours (4-hour
infusion time)
Appendix 8. Antimicrobial therapy for biliary
IAIs in critically ill patients presenting with
ESBL-associated risk factors (WSES
recommendations)
Community-acquired biliary IAIs
Critically ill patients (SEVERE SEPSIS)
Risk factors for ESBL
PIPERACILLIN
Daily schedule: 8 g by LD then 16 g via continuous
infusion or 4 g every 6 hours (4-hour infusion time)
+
TIGECYCLINE
Daily schedule: 100 mg LD then 50 mg every 12 hours
(2-hour infusion time)
+/−
FLUCONAZOLE
Daily schedule: 600 mg LD then 400 mg every 24 hours
(2-hour infusion time)
Appendix 9. Antimicrobial therapy for nosocomial
IAIs in stable, non-critical patients (WSES
recommendations)
Hospital-acquired IAIs
Stable, non-critical patients (< SEVERE SEPSIS)
Risk factors for MDR pathogens
PIPERACILLIN
Daily schedule: 8 g by LD then 16 g via continuous
infusion or 4 g every 6 hours (4-hour infusion time)
+
TIGECYCLINE
Daily schedule: 100 mg LD then 50 mg every 12 hours
(2-hour infusion time)
+
FLUCONAZOLE
Daily Schedule: 600 mg LD then 400 mg every
24 hours (2-hour infusion time)
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nosocomial IAI in critically ill patients. (WSES
recommendations)
Hospital-acquired extra-biliary IAIs
Critically ill patients (≥SEVERE SEPSIS)
Risk factors for MDR pathogens
PIPERACILLIN
Daily schedule: 8 g by LD then 16 g via continuous
infusion or 4 g every 6 hours (4-hour infusion time)
+
TIGECYCLINE
Daily schedule: 100 mg LD then 50 mg every 12 hours
(2-hour infusion time)
+
ECHINOCANDIN
caspofungin (70 mg LD, then 50 mg daily),
anidulafungin (200 mg LD, then 100 mg daily),
micafungin (100 mg daily)
OR
MEROPENEM
Daily Schedule: 500 mg every 6 hours (6-hour infusion
time)
IMIPENEM
Daily Schedule: 500 mg every 4 hours (3-hour infusion
time)
DORIPENEM
Daily Schedule: 500 mg every 8 hours (4-hour infusion
time)
+
TEICOPLANIN
Daily Schedule: LD 12 mg/kg/12 h for 3 doses then
6 mg/kg every 12 hours (with TDM corrections/
adjustments – PD target 20–30 mg/L)
+
ECHINOCANDIN
caspofungin (70 mg LD, then 50 mg daily),
anidulafungin (200 mg LD, then 100 mg daily),
micafungin (100 mg daily)
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